Abbott/TheraSense: A Subtext Beyond the Diabetes Market?

Abbott's TheraSense acquisition clearly helps resurrect its flagging MediSense diabetes device business. It may also signal a new aggressiveness for Abbott as it emerges from the long shadow of an FDA consent decree.

The rationale behind Abbott Laboratories Inc. 's $1.2 billion, all-cash acquisition of TheraSense Inc. [See Deal] is both obvious and subtle. It gives TheraSense, which has a powerful alternate-site blood glucose monitoring technology, more resources to compete with market leaders in diabetes self-testing. It also expands the global reach of the smaller company, via the international sales organization of Abbott's existing MediSense Inc. unit. (Currently, TheraSense only sells directly in the US and Canada.) And it allows TheraSense to dedicate more resources to R&D and the development of integrated systems, including its continuous glucose monitoring system. Indeed, many believe TheraSense is the first to overcome the technology hurdles that have stalled other companies, including Medtronic Inc. 's MiniMed Inc. division. The hefty price tag for the TheraSense transaction includes a premium based on that possibility. It may also signal a new aggressiveness for Abbott as it emerges from the long shadow of an FDA consent decree.

The deal clearly helps resurrect Abbott's flagging MediSense Inc. diabetes device business. "It was a move Abbott had to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By 

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.

Johnson & Johnson MedTech: How To Scale Digital Solutions

 

J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By 

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.